Di Guglielmo's syndrome
Also known as: Disorder, Syndrome, Diseases, Condition
Methodology & AI Transparency ⓘ
Di Guglielmo's syndrome Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Di Guglielmo's syndrome (also termed Disorder or Syndrome) is an ICD-10-CM indexed diagnosis (C94.00) within Cancer, Oncology & Supportive Care.
- 2 Real-world patient consensus: Synonyms for Di Guglielmo's syndrome (C94.00): Disorder, Syndrome, Diseases (Cancer & Oncology).
- 3 Typical cash cost range: Clinicians assessing Di Guglielmo's syndrome focus on somatic oncogenic driver in Di Guglielmo's syndrome (C94.00: mutations) and targeted history.
- 4 Top reported side effects / signs: Key Cancer & Oncology biomarkers for Di Guglielmo's syndrome (C94.00): Comprehensive Metabolic & in Di Guglielmo's syndrome (C94.00: Organ Function Panel) & Pathology / Molecular in Di Guglielmo's syndrome (C94.00: Genomic Staging) (Guideline-concordant surveillance (C94.00)).
Ask our AI Specialists anything about Di Guglielmo's syndrome
What Is Di Guglielmo's syndrome?
Di Guglielmo's syndrome (also termed Disorder or Syndrome) is an ICD-10-CM indexed diagnosis (C94.00) within Cancer, Oncology & Supportive Care. Clinical evaluation centers on tissue biopsy with in Di Guglielmo's syndrome (C94.00: histopathology) alongside serial Comprehensive Metabolic & in Di Guglielmo's syndrome (C94.00: Organ Function Panel) tracking (Preserved renal/hepatic clearance (C94.00)) to guide individualized care.
Pathophysiology, Underlying Causes & Clinical Presentation
Di Guglielmo's syndrome (C94.00) alters cancer & oncology homeostasis through somatic oncogenic driver in Di Guglielmo's syndrome (C94.00: mutations); clinical remission targets Pathology / Molecular in Di Guglielmo's syndrome (C94.00: Genomic Staging) within Guideline-concordant surveillance (C94.00).
Common Symptoms & Clinical Signs
- • Presentation of Di Guglielmo's syndrome (C94.00): abnormality detected early in Di Guglielmo's syndrome (C94.00: on age-appropriate screening)
- • Secondary Di Guglielmo's syndrome clinical sign: persistent painless lump, in Di Guglielmo's syndrome (C94.00: non-healing ulcer/mole change,)
- • Symptom flares in Di Guglielmo's syndrome correlating with Comprehensive Metabolic & in Di Guglielmo's syndrome (C94.00: Organ Function Panel) deviation outside Preserved renal/hepatic clearance (C94.00)
- • Functional cancer & oncology impact requiring tissue biopsy with in Di Guglielmo's syndrome (C94.00: histopathology) evaluation (C94.00)
Di Guglielmo's syndrome Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | C94.00 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Cancer, Oncology & Supportive Care | NLM Clinical Tables |
| Diagnostic / Lab Marker: Comprehensive Metabolic & in Di Guglielmo's syndrome (C94.00: Organ Function Panel) | Preserved renal/hepatic clearance (C94.00) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Pathology / Molecular in Di Guglielmo's syndrome (C94.00: Genomic Staging) | Guideline-concordant surveillance (C94.00) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Complete Blood Count in Di Guglielmo's syndrome (C94.00: (ANC, Hemoglobin, Platelets)) | Safe hematologic reserve (C94.00) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Di Guglielmo's syndrome
Treatment selection for Di Guglielmo's syndrome depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Di Guglielmo's syndrome)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| Pembrolizumab with chemoradiotherapy followed by pembrolizumab for stage III-IVa cervical cancer: is the ENGOT-cx11/GOG-3047/KEYNOTE-A18 trial practice changing? The associated costs render it unattainable in the regions where burden of cervical cancer is highest. Cancer • 2025-02-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 39913282 ↗ |
| New Insights on Bone Biomarkers and Subsequent Survival in Men with Hormone-sensitive Prostate: What a 316-Participant Study Found In men with HSPC initiating androgen deprivation therapy, bone biomarkers are strongly and independently prognostic for OS. European urology • 2024-02-15 • Phase III Randomized Trial | N = 316 | 87/100 | PMID 37085425 ↗ |
| New Insights on Nivolumab plus gemcitabine-cisplatin for unresectable or metastatic urothelial: What a 276-Participant Study Found Adding nivolumab to gemcitabine-cisplatin did not worsen HRQoL compared with gemcitabine-cisplatin alone in the first 16 weeks of therapy. ESMO open • 2026-03-15 • Phase III Randomized Trial | N = 276 | 87/100 | PMID 41747587 ↗ |
| Can This Approach Help? Inside the Latest Research on Cost-effectiveness of nivolumab in patients with NSCLC in the United Nivolumab is likely to be cost-effective for the treatment of patients with advanced NSCLC following platinum-based chemotherapy in the United States. The American journal of managed care • 2021-08-01 • Phase III Randomized Trial | Multi-cohort | 82/100 | PMID 34460179 ↗ |
| Can This Approach Help? Inside the Latest Research on External Validation of Association of Baseline Circulating Tumor Cell Counts with In this article, for the first time, we externally validate the association of higher CTC counts with inferior survival outcomes in men with mCSPC and show a distinct associated tumor genomic landscape. Molecular cancer therapeutics • 2022-12-02 • Phase III Randomized Trial | N = 103 | 82/100 | PMID 36198026 ↗ |
Di Guglielmo's syndrome Patient Community & “People Like Me” Threads
Filter Di Guglielmo's syndrome community threads and patient logs by age, biological sex, dosage, and treatment duration.